Navigation Links
Navigenics'(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments
Date:4/8/2008

REDWOOD SHORES, Calif., April 8, 2008 /PRNewswire/ -- Navigenics, a genetic health services company, today announced a new study of genetic predisposition analysis. The Mayo Clinic study will examine how patients understand and use information provided by a Navigenics genetic risk assessment. The research also addresses physicians' understanding of genetic assessments and the impact of such information on preventive health decision making. Titled "A Proof of Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment," the study begins this month and runs through September 2009. The study is funded jointly by Navigenics and Mayo Clinic.

"In this emerging field it is absolutely critical that the entire industry remain rooted in high-quality science and research - this is exactly what we do and what our customers, collaborators and advisors expect from Navigenics," said Mari Baker, president and CEO of Navigenics. "We believe this research collaboration with a leading medical institution like Mayo Clinic will help the entire industry evolve responsibly, provide the necessary tools to educate clinicians, and ultimately improve people's lives."

The Navigenics(TM) Health Compass is a new genetic risk assessment service that combines an advanced genome scan with the latest discoveries in genetic medicine and personalized genetic counseling. It gives individuals information on their genetic predisposition to developing a broad menu of common conditions, so that, with their physicians, they can seek earlier diagnosis, delay the onset or prevent the conditions altogether. The service calculates genetic predisposition based on genome-wide association studies that combine a variety of epidemiological variables. Navigenics scours the more than 4,000 published studies correlating genes to medical conditions and other common human traits to include only those which present high-quality and reliable results. The Navigenics Health Compass is the only personal genetic risk assessment to provide on-staff Certified Genetic Counselors to help people understand their individual results.

"The science that links genes with many common inherited diseases is well- established and growing," said Navigenics co-founder and clinical advisory board chair David Agus, M.D. "Now we need to better understand how individuals use this information. Navigenics hopes to learn more about patients' hopes and expectations regarding genetic risk assessment. Our goal is to leverage the wealth of information that genetics can provide to better motivate patients to take action that will improve their health. Our research collaboration with the Mayo Clinic helps us get there."

About Navigenics

Navigenics, Inc. is a privately held company based in Redwood Shores, Calif. The company was founded by David Agus, M.D. and Dietrich Stephan, Ph.D., with the goal of improving health outcomes in individuals across the population. Navigenics educates and empowers customers with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics' lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures. More information is available at http://www.navigenics.com.

FOR MORE INFORMATION:

Hal Mackins

Feinstein Kean Healthcare

Hal.mackins@fkhealth.com

(415) 677-2747

(415) 994-0040 - mobile

Brenna Sweeney

Navigenics

bsweeney@navigenics.com

(206) 999-4796


'/>"/>
SOURCE Navigenics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
2. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
3. Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
4. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
5. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
6. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
7. Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)
8. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 Today Stock-Callers.com have issued research ... Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences ... SSH ). These companies are part of the Healthcare sector, ... March 23 rd , 2017, with the NYSE Health Care ... care companies in the S&P 500 were down about 0.4% ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... Digital Scientists, a software innovation lab specializing in web ... Greenville, South Carolina location. The lab has set up shop at the ... working with South Carolina clients for years from our office here in Atlanta,” explains ...
(Date:3/24/2017)... ... 2017 , ... According to a new study by NCPA Senior Fellow John ... the rules Congress has directed the CBO to follow. The CBO itself previously recognized ... Yet, it estimates a reduction in employer-based coverage due to the GOP reform, which ...
(Date:3/24/2017)... ... 24, 2017 , ... The iaedp Foundation, the premier provider of educational programs ... suffering from the full spectrum of disordered eating, announced today that the 2017 Symposium ... all 50 states and several countries converged on the Green Valley Resort in Las ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
Breaking Medicine News(10 mins):